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INTRODUCTION
The innate immune system combats tissue injury and infection by activating the proinflammatory
responses involving the humoral complement system, granulocytes, macrophages and vascular
endothelial cells (VEC) (Newton and Dixit, 2012; Zhu et al., 2012). Macrophages mediate
proinflammatory responses by releasing inflammatory cytokines such as IL-1β. Once secreted,
IL-1β paracrinically acts on the VEC and massively change their functions. These perturbations
include a change from the anticoagulant phenotype to a procoagulant state, enhanced expression
of vasoactive substances, cell adhesion molecules as well as inflammatory mediators including
chemoattractants, and endothelial barrier dysfunction causing microvascular leakage (Pober and
Sessa, 2007). Although essential for the effective immune defense, uncontrolled or chronic
inflammatory response causes tissue damage and loss of organ function (Lon et al., 2012).
Increased IL-1β expression and an aberrantly activated IL-1β signaling explicitly correlates with
disease progression in a broad spectrum of local or systemic acute and chronic inflammatory
diseases such as severe systemic inflammatory response syndrome, sepsis, inflammatory bowel
disease and rheumatoid arthritis, and malignancies such as myeloma. In such diseases, blocking
IL-1β signaling with naturally occurring IL-1 receptor (IL-1R) antagonist (IL-1Ra) Anakinra
or neutralization with anti-IL-1β monoclonal antibody leads to abrupt and sustained decrease
in disease severity (Dinarello, 2011). The classical IL-1β pathway involves the binding of IL-
1β to IL-1R that results in the recruitment of the adapter protein MyD88 to the receptor’s
cytoplasmic domain. It is followed by the activation of IL-1R-associated kinases (IRAKs), and
phosphorylation inactivation of inhibitor of κB (iκB). The inactivated iκB is then targeted for
proteasomal degradation, thereby freeing NF-κB, the latter then translocates to the nucleus to
turn on the transcription of genes involved in inflammatory responses (Liu and Malik, 2006;
Dinarello, 2011). The standard approaches targeting IL-1β signaling by blocking its production
or interactions with IL-1R may arrest the NF-κB pathway. When NF-κB-dependent immune
responses critical for defense are interrupted, it renders the host immunocompromised and
susceptible to infections (Keane et al., 2001; Tak and Firestein, 2001; Zhu et al., 2012). Therefore,
strategies modulating IL-1β-mediated proinflammatory responses without affecting central NF-
κB activation or targeting a specific cell population like vascular endothelium are on great
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demand. Further, recent evidences suggest that
targeting a specific perturbation of IL-1β-activated
VEC (for example, enhanced immune cell attachment
or barrier dysfunction) may limit tissue destruction
(McCulloch et al., 2006; Zhu et al., 2012).
In the present study, we employed transcriptome profiling
to define the genes regulated by IL-1β signaling in the well-
established model of adult human immunocompetent primary
VEC, human coronary artery endothelial cells (HCAEC) (Zeuke
et al., 2002; Franscini et al., 2004). Here, we identify HGF as
one of the therapeutically relevant genes upregulated by IL-1β.
The gene ontology analysis suggests HGF’s critical involvement
in one of the most significant VEC monolayer barrier-injuring
biological pathways and inflammatory diseases enriched in IL-1β
transcriptome in VEC.
MATERIALS AND METHODS
Cell Culture
Human coronary artery endothelial cells (HCAEC) were
propagated and treated with recombinant human IL-1β (20
U/mL, PeproTech) as described previously (Skaria et al.,
2017a,b) and given in the Supplementary Methods. Detailed
information on endothelial cell characterization is given in
Supplementary Methods.
Differential Gene Expression Profiling
Microarray based gene expression profiling, as well as scanning,
feature extraction, and data normalization of microarrays
were carried out as described previously (Skaria et al., 2016,
2017b) and given in the Supplementary Methods. Entire
data sets of IL-1β-regulated transcriptome in HCAEC are
accessible in the NCBI GEO data repository, accession numbers:
GSE62281, GSE118297.
Microarray analysis using GeneSpring GX 9.0 Software
(Agilent Tech. Inc.) and MetaCoreTM GeneGO software
(Thomson Reuters, http://portal.genego.com) was carried
out as described previously (Skaria et al., 2016, 2017b) with
modifications and given in the Supplementary Methods.
DATA DESCRIPTION
Drug Targets in IL-1β-Regulated
Transcriptome of Adult Human VEC
The transcriptome profile of 4 h IL-1β-treated HCAEC was
compared to that of untreated HCAEC using whole human
genome oligomicroarrays. The genes in treated cells that
consistently exhibited a minimum two-fold change in expression
compared with untreated cells in preprocessed transcriptome
data were identified using GeneSpring analysis. IL-1β regulated
531 genes, of which 374 genes were upregulated and 157 genes
were down regulated (Supplementary Table S1).
To identify the genes regulated by IL-1β in HCAEC that
encode targets for known drugs and thus are of therapeutic
relevance, genes regulated at least two-fold in their expression
were subjected to drug target analysis using GeneGO software.
IL-1β regulated the gene expression of 26 direct drug targets,
of which 21 were upregulated (Supplementary Table S2) and
5 were down regulated (Supplementary Table S3). Among the
regulated targets (Supplementary Tables S2, S3), the expression
of genes such as COX-2, TNF-α, IL-6, IL-1β, MMP-1, GM-CSF,
ETS-1, NF-kB1, and c-Rel have been reported being modulated
in inflamed endothelium (Dinarello, 2011; Libby, 2017;
Skaria et al., 2017b).
Dysregulated HGF Expression Is Mapped
to VEC Monolayer Barrier-Injuring and
Repair Pathway
To our knowledge, the expression of genes such as CTSS,
HGF, PDE5A, and SRD5A2 (Supplementary Table S2) was not
previously reported being regulated by IL-1β in adult human
VEC. Therefore, we sought to investigate whether the regulated
expression of these genes as found in the present study
(Supplementary Tables S2, S3) critically modulates pathways
involved in proinflammatory response to IL-1β in adult human
VEC. To identify the most significant pathways regulated by
IL-1β in HCAEC, all genes regulated at least two-fold in their
expression were subjected to GeneGO functional enrichment
analysis (EA). The “Glomerular injury in Lupus Nephritis,”
“PDE4 regulation of cyto/chemokine expression in arthritis,”
“Immune response-IL-17 signaling pathways,” and “Immune
response-MIF-mediated glucocorticoid regulation” were the
first, second, third and fourth most statistically significant
pathways for IL-1β in HCAEC (Supplementary Figure S1).
The genes of these top four pathways regulated by IL-1β
(Supplementary Table S4) are the targets of NF-kB, the master
regulator of immune responses, and comprise a spectrum
of inflammatory cytokines (e.g., IL-1, IL-6), chemokines
(e.g., CCL2, CCL5), intercellular adhesion molecules (e.g.,
ICAM, VCAM), matrix metalloproteinases (e.g., MMP-1), and
prostaglandin (COX-2; Supplementary Table S4).
The “Vascular endothelial cell damage in SLE” was
the fifth most significant pathway for IL-1β in HCAEC
(Supplementary Figure S1). Among the genes regulated in
this pathway are HGF and the proinflammatory target genes
of NF-kB described above (Supplementary Table S4). The
MetaCore
TM
map of this pathway showing the genes within their
signaling context indicates that HGF regulates the monolayer
forming properties of the endothelium (Figure 1, upper left
quarter). The GO analyses listed the involvement of HGF in
128 disease states (Supplementary Tables S5, S6) and further
revealed “Vascular endothelial cell damage in SLE” as one out
of the total seven pathological pathway maps where HGF has
an established role (Supplementary Table S7). The “Immune
response_HMGB1/RAGE signaling pathway,” “Substance
P-mediated inflammation and pain in Sickle cell disease,”
“Immune response_IL-18 signaling,” “Signal transduction_NF-
kB activation pathways,” and “Immune response_Alternative
complement pathway” were the sixth, seventh, eighth, ninth, and
tenth most significant pathways regulated by IL-1β in HCAEC
(Supplementary Figure S1). The genes regulated by IL-1β in
the latter pathway are involved in complement activity while
those in the other four pathways are mainly the target genes
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FIGURE 1 | MetacoreTM map showing the signaling context of the genes contained in the “Vascular endothelial cell damage in SLE” pathway. Genes upregulated by
4 h IL-1β treatment are marked by red thermometer icons. Data are from three independent experiments.
of NF-kB associated with inflammatory responses involving
endothelial activation as described already in the top four
pathways (Supplementary Table S4).
Since IL-1β regulated HGF expression
(Supplementary Tables S1, S2) and the regulated HGF
expression has been mapped to one out of the 10 most
significant pathological pathways regulated by IL-1β
in HCAEC (Supplementary Figure S1: 5th pathway,
Supplementary Table S4), we next checked if HGF is
associated with the most significant disease profiles enriched
in IL-1β transcriptome. GeneGO functional EA analysis via
the biomarker assessment work flow revealed the critical
involvement of HGF in “Lupus Erythematosus, Systemic,” the
5th out of the ten most significant “Immune System Disease”
enriched in IL-1β transcriptome (Supplementary Figure S2,
Supplementary Table S8).
Targeting the inflammatory responses induced by the potent
innate immune proinflammatory cytokine IL-1β in VEC has been
found to reduce tissue damage and is emerging as a therapeutic
strategy to prevent loss of organ function during local and
systemic inflammatory diseases. Most often, studies aimed at
evaluating the inflammatory responses in adult human vascular
endothelial cells in vitro depend merely on cultured human
umbilical vein endothelial cells (HUVEC). HUVEC derived from
the immune naïve fetal tissue was subsequently reported to
exhibit significant differences in function compared with adult
humanVEC and thereforemay represent an inappropriatemodel
of adult human vascular endothelium (O’donnell et al., 2000; Tan
et al., 2004; Hwang et al., 2018). To study the proinflammatory
effects of IL-1β on adult human primary VEC, we used primary
endothelial cells isolated from adult human coronary artery,
that were positively tested for vascular endothelial markers and
function and are well-recognized as immunocompetent (Zeuke
et al., 2002; Franscini et al., 2004; Skaria et al., 2017b). IL-
1β treatments of HCAEC in this study were conducted for 4 h
since IL-1β is well-established as an early response cytokine and
capable of causing inflammatory gene induction and responses
as early as 4 h (Mizgerd et al., 2001; Sadeghi et al., 2015;
Skaria et al., 2017b). Here, we show that IL-1β upregulates the
gene expression of HGF, BDKRB2, CTSS, and SERT that are
critically involved in regulating VECmonolayer barrier function.
The expression of these genes was not previously reported
being regulated by IL-1β in adult human VEC. The functional
enrichment analysis maps HGF’s dysregulated expression to one
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of the most significant VEC monolayer barrier-injuring and
repair pathways, and inflammatory diseases enriched in IL-1β
transcriptome in VEC.
FUTURE DIRECTIONS
Besides systemic lupus erythematosus, several acute systemic
inflammatory diseases like systemic inflammatory response
syndrome and sepsis show altered plasma levels of both HGF
and IL-1β (Sakon et al., 1996; Matsushima et al., 2004; Sekine
et al., 2004). In these disease states, VEC barrier breakdown
and subsequent hyperpermeability leading to tissue edema
represents a critical factor contributing to the morbidity and
mortality (Weis, 2008; Chava et al., 2012). Therefore, the present
finding that IL-1β induces HGF in VEC raises important
questions whether (1) IL-1β-activated VEC represents a major
source of increased HGF levels in IL-1β-associated inflammatory
diseases, (2) HGF has a role in regulating IL-1β-induced VEC
injury and dysfunction, (3) therapeutically targeting HGF exerts
beneficial or deleterious effects on VEC barrier integrity and
function in pathophysiological states. Similar studies should
also be performed to evaluate the critical roles and benefits
of therapeutic targeting of BDKRB2, CTSS, and SERT, which
were previously found to contribute to VEC dysfunction and
are found to be induced by IL-1β in human VEC in the
present study.
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